An Open-Label Dose-Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients

Overview

Journal J Clin Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2017 Jun 10

PMID 28597919

Citations 4

Authors

Elaine Rutherford

Graham Stewart

J Graeme Houston

Alan G Jardine

Patrick B Mark

Allan D Struthers

Affiliations

Soon will be listed here.

Citing Articles

Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.

Steelandt A, Hittinger A, Kanagaratnam L, Kazes I, Clavel P, Bolko L BMC Nephrol. 2024; 25(1):266.

PMID: 39164615 PMC: 11334598. DOI: 10.1186/s12882-024-03712-w.

Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.

Anders H, Li Q, Steiger S Clin Kidney J. 2023; 16(6):928-938.

PMID: 37261000 PMC: 10229286. DOI: 10.1093/ckj/sfad006.

Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Stamp L, Farquhar H, Pisaniello H, Vargas-Santos A, Fisher M, Mount D Nat Rev Rheumatol. 2021; 17(10):633-641.

PMID: 34331037 PMC: 8458096. DOI: 10.1038/s41584-021-00657-4.

A Randomized, Controlled Trial of the Effect of Allopurinol on Left Ventricular Mass Index in Hemodialysis Patients.

Rutherford E, Ireland S, Mangion K, Stewart G, MacGregor M, Roditi G Kidney Int Rep. 2021; 6(1):146-155.

PMID: 33426394 PMC: 7783562. DOI: 10.1016/j.ekir.2020.10.025.

References

Hsu S, Pai M, Peng Y, Chiang C, Ho T, Hung K . Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2004; 19(2):457-62. DOI: 10.1093/ndt/gfg563. View

Bayram D, Sezer M, Inal S, Altuntas A, Kidir V, Orhan H . The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2014; 19(3):443-9. DOI: 10.1007/s10157-014-1012-z. View

Rekhraj S, Gandy S, Szwejkowski B, Nadir M, Noman A, Houston J . High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013; 61(9):926-32. DOI: 10.1016/j.jacc.2012.09.066. View

Guthikonda S, Sinkey C, Barenz T, Haynes W . Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 2003; 107(3):416-21. DOI: 10.1161/01.cir.0000046448.26751.58. View

Odudu A, Eldehni M, McCann G, McIntyre C . Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients. Clin J Am Soc Nephrol. 2015; 10(8):1408-17. PMC: 4527015. DOI: 10.2215/CJN.00200115. View

Thurston M, Phillips B, Bourg C . Safety and efficacy of allopurinol in chronic kidney disease. Ann Pharmacother. 2013; 47(11):1507-16. DOI: 10.1177/1060028013504740. View

Szwejkowski B, Gandy S, Rekhraj S, Houston J, Lang C, Morris A . Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013; 62(24):2284-93. DOI: 10.1016/j.jacc.2013.07.074. View

Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F . Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006; 17(5):1466-71. DOI: 10.1681/ASN.2005090949. View

Foley R, Parfrey P, Harnett J, Kent G, Murray D, Barre P . The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995; 5(12):2024-31. DOI: 10.1681/ASN.V5122024. View

10.

Johnson R, Nakagawa T, Jalal D, Sanchez-Lozada L, Kang D, Ritz E . Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant. 2013; 28(9):2221-8. PMC: 4318947. DOI: 10.1093/ndt/gft029. View

11.

Kao M, Ang D, Gandy S, Nadir M, Houston J, Lang C . Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011; 22(7):1382-9. PMC: 3137586. DOI: 10.1681/ASN.2010111185. View

12.

Larsen K, Pottegard A, Lindegaard H, Hallas J . Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. PLoS One. 2016; 11(1):e0146172. PMC: 4709004. DOI: 10.1371/journal.pone.0146172. View

13.

Wilson J, Goralski K, Soroka S, Morrison M, Mossop P, Sleno L . An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol. 2014; 54(8):901-9. DOI: 10.1002/jcph.335. View

14.

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

15.

George J, Struthers A . The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther. 2008; 26(1):59-64. DOI: 10.1111/j.1527-3466.2007.00029.x. View

16.

Kanbay M, Yilmaz M, Sonmez A, Solak Y, Saglam M, Cakir E . Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012; 36(4):324-31. DOI: 10.1159/000342390. View

17.

Pacher P, Nivorozhkin A, Szabo C . Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58(1):87-114. PMC: 2233605. DOI: 10.1124/pr.58.1.6. View

18.

Suliman M, Johnson R, Garcia-Lopez E, Qureshi A, Molinaei H, Carrero J . J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006; 48(5):761-71. DOI: 10.1053/j.ajkd.2006.08.019. View

19.

Rajendra N, Ireland S, George J, Belch J, Lang C, Struthers A . Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011; 58(8):820-8. DOI: 10.1016/j.jacc.2010.12.052. View

20.

Dawson J, Jeemon P, Hetherington L, Judd C, Hastie C, Schulz C . Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension. 2013; 62(1):105-11. DOI: 10.1161/HYPERTENSIONAHA.113.00859. View